An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg
Status:
Completed
Trial end date:
1998-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to examine the OROS® Hydromorphone HCL
pharmacokinetic (the way a drug enters and leaves the blood and tissues over time) profile
for dose proportionality after administration of 8mg, 16mg, 32mg and 64 mg tablets.